微小RNA（miRNAs）是一类大量的小型非编码单链RNA，其在细胞中具有表观遗传学上的重要作用，参与了基因表达以及其他生物学过程，并且可以被视为癌症早期检测和治疗管理的有能力的生物标志物。本综述旨在总结miR-647在不同癌症中的分子机制、靶基因和临床意义的相关证据。多项研究已经表明，在多种恶性肿瘤中都能发现miR-647的异常表达，比如膀胱癌、宫颈癌、结直肠癌、胃癌、胶质瘤、肝细胞癌、非小细胞肺癌、卵巢癌和前列腺癌，明显地，miR-647的表达增加或减少使其在肿瘤发生（癌性miR）或抑制基因中发挥作用。miR-647在增殖、迁移和侵袭肿瘤细胞中发挥作用，通过参与细胞周期途径。miR-647可以成为评估癌症程度、预后和治疗反应的有价值潜在生物标志物，并且在不同实体瘤中显示出很大的治疗功效。此外，miR-647的血清浓度直接影响整体生存率和疾病进展。因此，通过抗肿瘤药物对miR-647表达产生影响可能是一种高效的治疗靶点。版权所有：© 2023 Advanced Biomedical Research.

MicroRNAs are a large group of small, non-coding ssRNAs (miRNAs) that have an epigenetically pivotal role in gene expression and other biological processes in cells and can be regarded as capable biomarkers for the early detection and management of cancer. The aim of the present review article is to summarize the evidence for recognizing the molecular mechanism, target genes, and clinical significance of miR-647 in different cancers. Multiple studies have demonstrated that aberrant expression of miR-647 could be found in a variety of malignancies, such as bladder cancer, cervical cancer, colorectal cancer, gastric cancer, glioma, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, and prostate cancer have reported, notably, increase or decrease in expression of miR-647 so that it can function as a tumorigenic (oncomiR) or tumor suppressor gene. MiR-647 is effective in the proliferation, migration, and invasion of cancer cells by playing a function in cell cycle pathways. MiR-647 can be a valuable potential biomarker for assessing the extent of cancer, prognosis, and response to therapy and shows great therapeutic efficacy in different solid tumors. Moreover, serum concentrations of miR-647 are directly effective in decreasing overall survival and disease progression. So, an efficient therapeutic target can be the effect on miR-647 expression by antitumor drugs.Copyright: © 2023 Advanced Biomedical Research.